A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a double-blind randomised controlled study to evaluate the effectiveness of
orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and
duration of migraines in otherwise healthy participants aged 18 years and older.